| Name | Title | Contact Details |
|---|
SkyWater is a solely U.S.-based and owned, DMEA-accredited Technology Foundry, providing custom design and development services, exclusive design IP, and volume manufacturing for integrated circuits and micro devices. The Company`s world-class operations and unique processing capabilities enable mixed-signal CMOS, rad-hard and ROIC solutions. SkyWater`s Innovation Engineering Services empower development of superconducting and 3D ICs, along with carbon nanotube, photonic and MEMS devices. SkyWater serves customers in growing markets such as aerospace & defense, automotive, cloud & computing, consumer, industrial, IoT and medical.
Palma Ceia SemiDesign (PCS) is a fabless semiconductor company and leading provider of communication semiconductors and IP for next-generation Wi-Fi and cellular applications. With a focus on emerging Wi-Fi and LTE standards, particularly for IoT (Internet of Things), PCS targets the design of ICs for broadband, wireless, medical, and automotive applications. Palma Ceia SemiDesign solutions are differentiated by low power, high performance, and ease of integration. Headquartered in the Cayman Islands, the company has design and sales support centers in Cambridge (United Kingdom), mainland China, Hong Kong, and McKinney, Texas (United States). PCS is soon expanding to provide direct support for Israel, Japan, Korea, and Taiwan.
International Microelectronics And Packaging Society is a Washington, DC-based company in the Computers and Electronics sector.
Analog Bits is a Sunnyvale, CA-based company in the Computers and Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.